Recent Updates
Recently added Catalysts
OVID Positive Sentiment

Graviton Biosciences

Friday, September 22, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Graviton Biosciences and Ovid have partnered to develop OV888 and other ROCK2 inhibitors aimed at treating neurological conditions. Graviton will manage the development through Phase 2 trials, while Ovid will handle costs and commercialization beyond that phase. This collaboration highlights a commitment to addressing neurological disorders characterized by seizures and spasms.
Price reaction · baseline $3.5 (2023-09-22T16:00:00.000Z) · hit during market hours · 31 other OVID headline(s) in the window, move may be shared
day 0 close · peak
+4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration between Graviton and Ovid to advance OV888.
  • Focus on developing ROCK2 inhibitors for neurological conditions.
  • Joint development committee oversight ensures collaborative progress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+622%
120-day peak, hindsight
Typical move
2.4%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk

Full Press Release Details

In April 2023, Graviton and Ovid entered into a collaboration and license agreement to advance the development of OV888, along with other selective, small-molecule compounds from a library of ROCK2 inhibitors that have shown blood-brain barrier penetrance. Together, the companies intend to develop ROCK2 inhibitors for the treatment of a broad range of neurological conditions marked by seizures, spasms, and related symptoms. Under this agreement, Graviton will be responsible for conducting the development of the products through the end of Phase 2 trials under the oversight of a joint development committee from both companies. Ovid will be responsible for development and commercialization costs, as well as post-Phase 2 development, and commercialization of the products.
Read Ovid press release »

Frequently Asked Questions

What is the purpose of the Graviton and Ovid collaboration?

The collaboration aims to develop OV888 and other ROCK2 inhibitors for neurological conditions.

Who is responsible for Phase 2 trials in the partnership?

Graviton will conduct the development through the end of Phase 2 trials.

What are ROCK2 inhibitors used for?

ROCK2 inhibitors are intended for treating neurological conditions marked by seizures and spasms.

What costs will Ovid cover in the agreement?

Ovid will handle development and commercialization costs post-Phase 2.

ShareAdd on Google
Tags: OVID Viatris Investor Conferences Healthcare Graviton Ovid ROCK2 inhibitors neurological conditions collaboration
Last updated: Sep 22, 2023

Biotech snapshot

Cash runway
$166M liquidity · $5M/mo burn
~33 mo
Minimal dilution risk

Catalyst track record

+622%
best trade around OVID's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for OVID.

See every catalyst's timing & PoA →